Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children’s Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Beam Therapeutics Inc. (BEAM)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
5 days ago | Zacks Investment Research
5 days ago | GlobeNewsWire
a week ago | Zacks Investment Research
a week ago | GlobeNewsWire
a month ago | The Motley Fool
a month ago | GlobeNewsWire
a month ago | The Motley Fool
2 months ago | GlobeNewsWire
3 months ago | Benzinga
3 months ago | Zacks Investment Research